Survodutide is an investigational dual GLP-1/glucagon receptor agonist under active evaluation for metabolic dysfunction-associated steatohepatitis (MASH).
Read more Survodutide in MASH Research: Clinical Evidence and Hepatic Mechanisms
Survodutide is an investigational dual GLP-1 and glucagon receptor agonist undergoing clinical evaluation for obesity and metabolic dysfunction-associated
Read more Survodutide Studies: Evaluating Dual GLP-1 and Glucagon Agonism in Clinical Research
An evidence-based scientific review of survodutide (BI 456906), exploring its dual GLP-1 and glucagon receptor agonism, Phase 2 trial results in MASH and o
Read more Survodutide: Mechanism of Action and Clinical Trial Evidence
Survodutide is a dual GLP-1 and glucagon receptor agonist demonstrating potent efficacy across clinical trials for obesity, metabolic dysfunction, and stea